Press Releases

NESS ZIONA, Israel, Sept. 30, 2019 /PRNewswire/ -- BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, today announced that BiomX's Chief Executive Officer, Jonathan Solomon, will present at the Cantor Fit

NESS ZIONA, Israel, Sept. 30, 2019 /PRNewswire/ -- BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, today presented new data from the company's colorectal cancer synthetic biology program at the Fifth CRI-CIMT-EATI-AACR International

ROCKVILLE, Md., Sept. 30, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the Chardan 3rd Annual Genetic Medicines Conference on Monday,

CAMBRIDGE, Mass., Sept. 30, 2019 /PRNewswire/ -- SmartPharm Therapeutics, a preclinical-stage pharmaceutical company focused on developing next-generation, non-viral gene therapies for the treatment of rare diseases, today announced that José Trevejo, MD, PhD, President and Chief Executive Officer, will present at the Chardan 3rd Annual Genetic Medicine

NEW YORK and LONDON, Sept. 30, 2019 /PRNewswire/ -- CK Hutchison Holdings Limited ("CKHH") announces its intention to sell approximately 1.3% of the total outstanding share capital in Hutchison China MediTech Limited ("Chi-Med") through an underwritten public offering, which would reduce its stake in Chi-Med from 51.1% to 49.9% (the "Offering"). CKHH also ann

SAN FRANCISCO, Sept. 30, 2019 /PRNewswire/ -- Gryphon Investors ("Gryphon"), a San Francisco-based middle-market private equity firm, announced today that it has entered definitive documentation to sell its portfolio company ECG Management Consultants ("ECG" or "the Company") to Siemens Medical Solutions USA

WILLOWBROOK, Ill., Sept. 30, 2019 /PRNewswire/ -- Pharmazz, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, today announced that it made 5 presentations at the Sixteenth International Conference on Endothelin held in Kobe, Japan from

STAINES-UPON-THAMES, United Kingdom, Sept. 30, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), along with its wholly owned subsidiaries Mallinckrodt LL

SAN DIEGO, Sept. 30, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management's participation in the following investor and scientific conferences in October:

WINNIPEG, Sept. 30, 2019 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce that through its subsidiary, Medicure International Inc., it has acquired the ownership of ZYPITAMAGTM (pitavastatin) tablets, from Cadila Healthcare Ltd., India